Outset Medical, Inc. (NASDAQ:OM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Outset Medical, Inc. (NASDAQ:OM) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $12.6667.

Several brokerages recently commented on OM. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 price objective on shares of Outset Medical in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus set a $14.00 target price on Outset Medical and gave the stock a “buy” rating in a report on Tuesday, November 11th. Finally, BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Outset Medical in a report on Tuesday, December 16th.

Outset Medical Stock Performance

Outset Medical stock opened at $3.70 on Wednesday. Outset Medical has a twelve month low of $3.10 and a twelve month high of $25.35. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $67.16 million, a P/E ratio of -0.28 and a beta of 2.07. The stock’s 50 day moving average is $6.13 and its 200 day moving average is $12.33.

Hedge Funds Weigh In On Outset Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new stake in shares of Outset Medical in the second quarter worth approximately $34,000. Ameritas Investment Partners Inc. purchased a new stake in Outset Medical in the second quarter worth approximately $35,000. BNP Paribas Financial Markets grew its position in Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after purchasing an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in Outset Medical in the 2nd quarter worth approximately $78,000. Finally, New York State Common Retirement Fund bought a new stake in Outset Medical in the 2nd quarter worth approximately $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.